Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 1
11(73.3%)
N/A
2(13.3%)
Phase 2
1(6.7%)
Early Phase 1
1(6.7%)
15Total
Phase 1(11)
N/A(2)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT07169500Phase 1Recruiting

Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

Role: collaborator

NCT07259070Phase 1Not Yet Recruiting

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

Role: collaborator

NCT07249073Early Phase 1Recruiting

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

Role: collaborator

NCT07117305Phase 1Not Yet Recruiting

CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT07109323Phase 1Recruiting

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Role: collaborator

NCT07106723Phase 2Recruiting

Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

Role: collaborator

NCT05618041Not ApplicableRecruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Role: collaborator

NCT05388695Phase 1Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Role: collaborator

NCT07008872Not ApplicableNot Yet Recruiting

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Role: collaborator

NCT06917105Phase 1Not Yet Recruiting

Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

Role: collaborator

NCT06911710Phase 1Recruiting

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Role: collaborator

NCT06735495Phase 1Recruiting

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Role: collaborator

NCT06720324Phase 1Recruiting

CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors

Role: collaborator

NCT06503094Phase 1Recruiting

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Role: collaborator

NCT06503107Phase 1Recruiting

Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM

Role: collaborator

All 15 trials loaded